KRAS and neoplasm: Upstream RTK regulators (EGFR, HER2, FGFR, cMET, and SHP2), direct mediators of KRAS activation (AURKA), and/or effectors of MAPK and PI3K pathways may escape form KRAS G12C inhibition, with different mechanisms depending on the tumor tissue type [9].